Skip to main content
Signal8

Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline

$LIMNPress releaseMay 21, 2026, 8:04 AM ET

Liminatus Pharma has entered a definitive merger agreement to acquire InnocsAI, a biotechnology company focused on advanced CAR-T and antibody-based oncology therapies. The transaction values InnocsAI at approximately $320 million, with existing members receiving 1.6 billion shares of Liminatus common stock at $0.20 per share, plus contingent value rights for 20% of future net proceeds from strategic transactions.

Key figures

Deal Value Usd
320000000
Offering Price
0.2
Shares Offered
1600000000
Cvr percentage
20%

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.